Received Aug 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | UNK | — | — |
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | U8335AA | IM / LL |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | UNK | Y007989 | IM / LL |
patient inadvertently received RECOMBIVAX HB and VAXELIS on the same day; patient inadvertently received RECOMBIVAX HB and VAXELIS on the same day; This non-serious spontaneous safety report, with reference number 02809187 (Interaction# 02809129), was received by a partner on 21-MAY-2025 and forwarded on 21-MAY-2025 from a Nurse Practitioner. The reporter did not assess the causal relationship between Vaxelis and the reported events of "patient inadvertently received RECOMBIVAX HB and VAXELIS on the same day." Due to the nature of the event, the causality between the events "Extra dose administered", "Overdose" and Vaxelis was not applicable. Further information is expected. Significant follow-up information was received by the other health professional on 28-MAY-2025 and forwarded on 29-MAY-2025. The case is maintained as non-serious. The reporter did not assess the causal relationship between Vaxelis and the reported events of "patient inadvertently received RECOMBIVAX HB and VAXELIS on the same day." Due to the nature of the events, the causality between the event and Vaxelis was not applicable. Further information is not expected. This case was retrieved during the Vaccines Adverse Event Reporting System (VAERS) monitoring on 16-JUL-2025 with the following VAERS primary ID: 2842556-1. The original narrative from the sender is AS FOLLOWS: the patient inadvertently received RECOMBIVAX HB and VAXELIS on the same day.; No symptomatic adverse events were reported.; This spontaneous report was received from a nurse and refers to a(n) patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 20-May-2025, the patient was inadvertently vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) and diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus (VAXELIS) for the treatment of Prophylaxis (strength, specific dosage, dose number, route of administration, anatomical site of application, lot number and expiration date were not provided). No symptomatic adverse events were reported. This is one of two reports received from the same reporter.; Reporter's Comments: Due to the nature of the event, the causality between the events 'Extra dose administered, Overdose' and Vaxelis was not applicable. No further information is expected.
Premature baby 33 to 36 weeks; Prophylaxis
Medical History/Concurrent Conditions: GERD; Plagiocephaly; Retinopathy of prematurity
PREVENAR 20